Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Post by HighteawithIntrepidon Sep 09, 2017 5:07pm

245 Views

Post# 26676041

Q2 financials

On August 11, 2017, the Corporation entered into definitive agreements with affiliates of Shenzhen Royal Asset Management Co., Ltd. (collectively “SRAM”) to develop and commercialize PBI-4050, PBI-4547 and PBI-4425 in the People’s Republic of China (excluding Hong Kong, Taiwan and Macau). Under the agreements, SRAM will pay the Corporation an upfront payment of $13.0 million (US$10.0 million) and a first milestone payment of $9.1 million (US$7.0 million), as well as a further $10.5 million (US$8.0 million) over the following years based on completion of further development and regulatory milestones.
So from the financial statements and my paper trail the 13 million is a Q3 receipt so copy
and paste the 9.1 million going from a milestone to cash otherwise I'm not willing to recognize it until I see a press release or PLI puts it in the Q3 financial statements. And if I represent the lost and confused market that is one of PLI's problems and why the share price is where it is. So if anyone has PL's ear clarify that by Monday's fireside chat.